Distribution of GVHD risk factors in patients with a non-CC and CC genotype donor
| Variable . | Percentage (absolute number) . | |
|---|---|---|
| Donor with non-CC genotype (n=266) . | Donor with CC genotype (n=20) . | |
| Patient age median (range) | 59 (20-75) | 55 (22-77) |
| Donor age median (range) | 39 (18-74) | 42.5 (19-62) |
| Matched related donor | 27% (72) | 30% (6) |
| Matched unrelated donor | 38% (101) | 35% (7) |
| HLA mismatch | 35% (93) | 35% (7) |
| Fludarabine-based conditioning | 82.3% (219) | 75% (15) |
| Bu/Cy or TBI | 17.7% (47) | 25% (5) |
| CSA | 95.9% (255) | 95% (19) |
| Campath | 74.4% (198) | 65% (13) |
| MMF | 11.7% (31) | 20% (4) |
| ATG | 9.4% (25) | 15% (3) |
| Number of T cells in the graft (×108/kg BW; mean ± SD) | 3.02 ± 2.61 | 2.38 ± 1.05 |
| Variable . | Percentage (absolute number) . | |
|---|---|---|
| Donor with non-CC genotype (n=266) . | Donor with CC genotype (n=20) . | |
| Patient age median (range) | 59 (20-75) | 55 (22-77) |
| Donor age median (range) | 39 (18-74) | 42.5 (19-62) |
| Matched related donor | 27% (72) | 30% (6) |
| Matched unrelated donor | 38% (101) | 35% (7) |
| HLA mismatch | 35% (93) | 35% (7) |
| Fludarabine-based conditioning | 82.3% (219) | 75% (15) |
| Bu/Cy or TBI | 17.7% (47) | 25% (5) |
| CSA | 95.9% (255) | 95% (19) |
| Campath | 74.4% (198) | 65% (13) |
| MMF | 11.7% (31) | 20% (4) |
| ATG | 9.4% (25) | 15% (3) |
| Number of T cells in the graft (×108/kg BW; mean ± SD) | 3.02 ± 2.61 | 2.38 ± 1.05 |
Fludarabine-based conditioning includes fludarabine/melphalan/bis-chlorethyl nitrosourea, fludarabine/melphalan/thiotepa, fludarabine/thiothepa/treosulfan, fludarabine/bis-chlorethyl nitrosourea/thiotepa, fludarabine/melphalan, fludarabine/treosulfan, and fludarabine/thiothepa.
ATG, antithymocyte globuline; Bu/Cy, busulfan, cyclophosphamid; BW, body weight; CSA, cyclosporine A; MMF, mycophenolic acid; SD, standard deviation; TBI, total body irradiation.